Markets
Futures
US
Europe
Asia
Currencies
Crypto
HomeAMRN • NASDAQ
Amarin Corporation plc
Follow
$0.79
Pre-market: $0.79
Closed: Jul 26, 8:22:06 AM GMT-4 · USD · NASDAQ · Disclaimer
Key events shows relevant news articles on days with large price movements Key events shows relevant news articles on days with large price movements Key events shows relevant news articles on days with large price movements
MTNB
$0.17
MTNB0.00%
Amazon.com Inc
$179.85
AMZN0.00%
Akebia Therapeutics Inc
$1.48
AKBA0.68%
RedHill Biopharma Ltd
$0.38
RDHL0.00%
Aurinia Pharmaceuticals Inc
$5.60
AUPH0.72%
Sangamo Therapeutics Inc
$0.67
SGMO0.00%
FuelCell Energy Inc
$0.54
FCEL0.00%
ANI Pharmaceuticals Inc Common Stock
$62.03
ANIP1.94%
Heron Therapeutics Inc
$3.10
HRTX1.59%
Ardelyx Inc
$5.49
ARDX0.00%
In the news
Financials
Income Statement
Revenue Net income Fiscal Q1 2024 ended 3/31/24. Reported on 5/1/24. Revenue The total amount of income generated by the sale of goods or services related to the company's primary operations Operating expense Represents the total incurred expenses through normal operations Net income Company’s earnings for a period net of operating costs, taxes, and interest Net profit margin Measures how much net income or profit is generated as a percentage of revenue. Earnings per share Represents the company's profit divided by the outstanding shares of its common stock. EBITDA Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance and is used as an alternative to net income in some circ*mstances Effective tax rate The percent of their income that a corporation pays in taxes(USD) Mar 2024info Y/Y change 56.52M -34.26% 45.49M -30.31% -9.95M 39.53% -17.61 8.04% -0.01 -150.00% -12.82M -196.65% -15.00% —
Balance Sheet
Total assets Total liabilities Fiscal Q1 2024 ended 3/31/24. Reported on 5/1/24. Cash and short-term investments Investments that are relatively liquid and have maturities between 3 months and one year Total assets The total amount of assets owned by a company Total liabilities Sum of the combined debts a company owes Total equity The value of subtracting the total liabilities from the total assets of a company Shares outstanding Total number of common shares outstanding as of the latest date disclosed in a financial filing Price to book A ratio used to determine if a company’s market value is in line with the value of its assets less liabilities and preferred stock Return on assets A financial ratio that shows a company’s profitability compared to its assets Return on capital Company’s return above the average cost it pays for its debt and equity capital(USD) Mar 2024info Y/Y change 308.18M 1.25% 790.01M -8.16% 244.08M -11.37% 545.94M — 410.87M — 0.59 — -4.19% — -6.07% —
Cash Flow
Net change in cash Fiscal Q1 2024 ended 3/31/24. Reported on 5/1/24. Net income Company’s earnings for a period net of operating costs, taxes, and interest Cash from operations Net cash used or generated for core business activities Cash from investing Net cash used or generated in investing activities such as purchasing assets Cash from financing Net cash used or generated in financing activities such as dividend payments and loans Net change in cash The amount by which a company's cash balance increases or decreases in an accounting period Free cash flow Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments(USD) Mar 2024info Y/Y change -9.95M 39.53% -12.60M -79.81% 28.72M 246.45% -1.43M -491.76% 14.69M 155.96% -12.69M 6.80%
US listed security Listed on NASDAQ Headquartered in Dublin, Leinster, Ireland
Previous close The last closing price
$0.78
Day range The range between the high and low prices over the past day
$0.78 - $0.80
Year range The range between the high and low prices over the past 52 weeks
$0.63 - $1.37
Market cap A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
325.08M USD
Avg Volume The average number of shares traded each day over the past 30 days
1.46M
About
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia CEO Karim Mikhail Founded Mar 1, 1989 Headquarters Dublin, LeinsterIreland Website Employees 275
Discover more
You may be interested in
info This list is generated from recent searches, followed securities, and other activity. Learn more All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
People also search for
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
add_circle_outline
HelpSend feedbackPrivacyTermsDisclaimer